theMednet

In mCRPC patients who had an initial response to Pluvicto but progress within 12 months, where do you position PSMA radioligand retreatment relative to other next-line systemic options in your sequencing strategy?

www.themednet.org/v2/programs/199/questions?mode=question&questionId=27604"

Link to relevant Q&A:

What criteria are you using for retreatment with Pluvicto (Lu-177) in those who maintain a good performance status and appropriate lab work?

www.themednet.org/v2/programs/199/questions?mode=question&questionId=20197"

The American Society for Radiation Oncology (ASTRO) #MRPTS26 plenary session on Radiopharmaceutical Retreatment (Plenary II) just concluded.

Dr. Ana Kiess is answering questions now on theMednet.

Head to the Q&A → www.themednet.org/v2/programs/199/questions?mode=question&questionId=20197

Link to relevant Q&A:

Does the possibility of future Lu-177–PSMA therapy change your current threshold to offer earlier metastasis-directed RT in oligometastatic prostate cancer?

www.themednet.org/v2/programs/199/questions?mode=question&questionId=27603

Link to relevant Q&A:

Can you give Pluvicto with concurrent palliative EBRT?

www.themednet.org/v2/programs/199/questions?mode=question&questionId=17105

The American Society for Radiation Oncology (ASTRO) #MRPTS26 plenary session on Clinical Outcomes among Patients Treated with Lu-PSMA-617 and EBRT for Oligometastatic Prostate Cancer just concluded.

Dr. Neil K Taunk is answering questions now on theMednet.

Links to relevant Q&A:

When selecting mCRPC patients for Pluvicto, which baseline variables do you find most useful or predictive of potential hematologic toxicity? - www.themednet.org/v2/programs/199/questions?mode=question&questionId=27602

Links to relevant Q&A:

Do you modify dosing and monitoring of Lu-177–PSMA therapy for patients with prior large-field RT involving substantial active marrow compared with patients who only had focal bone SBRT? - www.themednet.org/v2/programs/199/questions?mode=question&questionId=27601

The American Society for Radiation Oncology (ASTRO) #MRPTS26 plenary session on Hematologic Toxicity Outcomes of Lu-PSMA-617 in Patients Previously Treated with EBRT for Oligometastatic Disease just concluded.

Drs. Neil K Taunk & Krishnan R Patel are answering questions now on theMednet.

Links to relevant Q&A:

How do you sequence Pluvicto vs docetaxel in a fit, chemotherapy-naïve patient with high-volume PSMA-avid mCRPC progressing on an ARPI?  - www.themednet.org/v2/programs/199/questions?mode=question&questionId=27599

Links to relevant Q&A:

For patients starting Pluvicto, do you have patients stop their ARPI? - www.themednet.org/v2/programs/199/questions?mode=question&questionId=26213

ASTRO plenary session on Safety and Efficacy of Lu-177 PSMA-617 Versus Established Therapies in mCRPC: Pooled Evidence from Randomized Phase II/III Trials just concluded.

Dr. John Nikitas is answering questions now on theMednet.

Head to the Q&A → www.themednet.org/v2/programs/199/questions

Join the conversation to share perspectives, ask follow-up questions, and see how others are interpreting the findings.

Join the Conversation: www.themednet.org/v2/programs/...

Keep the Conversation Going with theMednet

We’re hosting dedicated Q&A on theMednet for studies featured in this week’s Plenary and Clinical Trials sessions at the ASTRO 2026 Multidisciplinary Radiopharmaceutical Therapy Symposium in Palm Desert, CA.

#MRPTS26

From Dr. Paul Sax’s NEJM blog (HIV and ID Observations): when the question isn’t “What do the guidelines say?” but “What would you actually do?”

Read the blog here: blogs.nejm.org/hiv-id-obser...

#InfectiousDiseases #NEJM #theMednet

Meet the team behind theMednet

Introducing Dan Ricotta, MD — Medical Director, General Internal Medicine and Geriatrics at theMednet, and Associate Professor of Medicine at Harvard Medical School.

Join the peer-to-peer conversation on theMednet.org.

How do you explain the use of an AI scribe to patients?

Join the Conversation: www.themednet.org/v2/question/...

#Psychiatry #HealthAI #DigitalHealth #PatientPrivacy #ClinicalDocumentation #PatientExperience